Artificial intelligence-enabled early intracranial volumetric response predicts systemic progression-free survival in the phase III CROWN study. (PubMed, Neurooncol Adv) - Sep 25, 2026 - P3 | "CROWN randomized patients to lorlatinib or crizotinib. Volumetric all-BMs ETR outperforming target-only mRECIST offers early prognostic information in advanced ALK-positive NSCLC. ClinicalTrials.gov identifier: NCT03052608."
Journal • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Chih-Hung Liang; Chong Duan; Erqi Pollom; Francesca Toffalorio; Giuseppe Giaccone; Jen-Tang Lu; Keith Wilner; Kevin Maresca; Po-Lin Chiang; Shao-Lun Lu; Yu-Cheng Chang
|